Next Phase Newsletter

A new venture capital firm with headquarters in Europe seeks to make 2-4 equity investments in the range from $1-5M (EUR) per year. The firm is actively seeking new investments globally, with a focus in USA and Europe.

The firm invests in technologies that can treat age-related disease and damages associated with aging, such as altered protein homeostasis, cellular senescence, stem cell exhaustion, etc. The firm will consider companies working in therapeutics, diagnostics, nutritional products and advanced therapy medicinal products (gene therapy, cell therapy, tissue engineering) as long as they are relevant to the firm’s mission in targeting the basic mechanisms contributing to age-related disease. However, medical devices are currently not an area of focus. In therapeutics, the firm looks mostly at pre-clinical technologies with a validated proof-of-concept. The firm will consider companies in their later stages but prefers working with early-stage companies to provide company building and strategic support.

The firm can work with all types of management teams. The firm places higher importance in the actual science or technology in development as well as solid IP position. The firm seeks to work closely with their portfolio companies and can assist with building and structuring a full management team. As the firm generally comes in as the first institutional investor, they prefer to lead rounds and take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences investment firm with a global diversified strategy ranging from seed stage to public companies, is actively involved in innovation, restructuring opportunities, and growth investing. The firm’s investment team brings a wealth of experience across all areas of the life sciences industry. Nearly all of the firm’s partners have been with the firm for 12 years or more, and they are supported by over 20 investment professionals, distinguished advisers, and scientific advisory board members. The firm has no set number of allocations that it plans to make but is actively reviewing new opportunities from around the globe. The firm has a history of strategic relationships with other venture capital firms or funds targeting specific sectors or geographies within the life sciences. These working relationships help give them a global footprint and vastly expand the firm’s deal flow.

The firm’s general life sciences funds represent approximately $1.3 billion in capital commitments. These funds target a diverse group of life sciences companies, across all stages of development. Bay City Capital funds have invested in a total of 100 portfolio companies covering a broad range of life science sectors, including biopharmaceuticals, drug discovery and research tools, medical devices, diagnostics, digital health, nutrition, and agribusiness.

The firm seeks to invest its capital in life sciences companies where their operational, financial, and scientific expertise can assist management in building companies. This investment approach has remained largely consistent since 1997, delivering attractive returns to their investors. Effective management is critical to the success of their portfolio companies. The firm assists their portfolio companies in recruiting and retaining key management and advisors, identifying product opportunities, establishing and negotiating strategic partnerships, and providing assistance with product development and execution. The firm develops close working relationships with their management teams to establish themselves as true partners in business building.

The firm strongly prefers board representation, and have received a board seat with 90% of their portfolio companies (based on invested capital). The firm believes this commitment of intellectual capital increases the likelihood of positive outcomes for their investments, and has established them as a preferred partner in the industry.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences Venture Capital firm based in Toronto with other offices throughout USA and Canada manages over $350M and is currently investing from a recently closed new fund. The firm typically makes initial investments ranging from $2-6 million of equity and looks to invest $8-12 million over the lifetime of the investment. The firm expects to make 4-6 investments over the next 12 months.

The firm invests primarily in therapeutics and medical devices, with selective investments in diagnostic imaging and digital health. The firm generally looks for companies phase I and later that have at least some human proof-of-concept with either early human efficacy signs or very strong animal data coupled with human safety data.

The firm invests in companies throughout the United States and Canada. The firm does not look to take an active role on the management team but does look to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early-stage venture capital firm based in the bay area is currently making Seed and Series A investments into companies ranging from $500K to $7 million, depending on the stage and financial requirements of the company – with up to $15 million over the company’s lifetime. The firm has a preference for companies based in Silicon Valley, but will consider opportunities globally.

The firm is sector agnostic having its main screening criteria be that the company is operating in a white space (meaning little or no competition) and having potential market sizes of at least $10 billion from a bottoms-up view. That being said, companies in the life science space that the firm is most interested in include medical technology, devices, and diagnostics for massive unmet markets such as diabetes, hypertension, and obesity. Additionally, the firm is interested in lab and provider service companies, although the firm is very sensitive to market size (need to meet the aforementioned market size). Areas where the firm has been involved previously include a genomic cardiovascular diagnostic, bioinformatics, lab services and other diagnostics companies.

The firm looks to be the first institutional investor in companies and acts as a lead or co-lead investor. The firm looks to take an active board seat into companies and assist with many aspects of the company’s development. The firm considers experienced management teams and a history of success as a strong plus, but is comfortable in working with first-time entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life-sciences focused venture capital firm is currently making investments out of its third fund. The firm primarily makes equity investment into seed and early stage rounds ranging from $250,000 to $1 million initially and up to $2 million over the lifetime of the investment. The firm is focused on companies located in Southern California and the Southwestern United States although they are open to review companies from throughout the US. The firm could make as many as 3 new investments over the next 6-9 months.

The firm is looking for companies in sectors of Therapeutics, Diagnostics, Medical Devices, Life Science Tools and Healthcare IT. The firm is agnostic in terms of subsectors and indications within these areas and is also interested in orphan indications and wireless medical devices. The firm looks to invest in early-stage companies including pre-clinical stage companies with some supporting in-animal data, although it is not a requirement.

The firm is looking for privately held companies with experienced management teams. The firm looks to play an active role as an investor and generally looks to take a board or board observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in New York, NY looks to invest in medical devices and diagnostics, but will also consider therapeutics and digital health. The firm prefers companies that have some proof of concept data, with some animal studies complete, and will invest through to clinical-stage companies. The firm generally co-invests in a syndicate, and will invest between $100-500K, depending on the stage of development of the company. The firm is currently interested in investing in companies located in North America.

The firm is focused primarily on medical devices and diagnostics, but will consider therapeutics, if they are first in class, and digital health, with a focus on AI-related technologies. The firm has focused on technologies related to oncology, diabetes and kidney diseases, but will consider other indications as well.

The firm is interested in companies with strong management teams. As the firm will generally co-invest, board representation is not usually required after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with multiple offices throughout the USA currently has approximately $350 million in total assets under management. The firm is making 2-3 new investments every month from its newest fund. The firm typically makes investments ranging from $0.25 million to $6 million over the life of the company. The firm prefers to invest early at the Seed, Series A and Series B stage. The firm will consider investing in any industry segment, but there must be at least one other venture capital firm making their first investment in the company in this round. The firm only invests in US-based companies.

The firm is currently looking for new investment opportunities in the life sciences space. The firm is very opportunistic in terms of sectors, subsectors and indications. The firm is currently active in therapeutics companies that develop nucleic acid drugs and small molecules to treat oncology and infectious diseases. The firm is also active in medical devices companies that develop active diagnostic and therapeutic radiation devices, implantable devices and surgical devices.

The firm seeks to invest in private companies based in US and only acts as a co-investor in financing rounds. The firm invests in companies that already have at least one other venture capital firm making their first investment. The best time to engage with the firm is when a company has a term sheet or expression of interest from another Venture Capital Firm.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.